2687-0940Challenges in modern medicine2687-094010.18413/2687-0940-2020-43-3-351-36435INTERNAL DISEASESEarly diagnostics of metabolic syndrome on the basis of non-invasive visualization of the hepatopancreatobiliary system organsEarly diagnostics of metabolic syndrome on the basis of non-invasive visualization of the hepatopancreatobiliary system organsShishovaIrina A.ShishovaIrina A.shishova@bsu.edu.ruEfremovaOlga A.EfremovaOlga A.efremova@bsu.edu.ruChernobayPavel Ye.ChernobayPavel Ye.AbdulganiShakhnozaAbdulganiShakhnoza202043300

The article presents the results of a study conducted to identify early significant markers of metabolic syndrome (MS) based on non-invasive visualization of the internal organs of the abdominal cavity. The study included 125 people, 100 people of the main group were divided into two subgroups. Subgroup I – patients with normative values of body mass index (BMI), but with increased indices of the waist circumference / hip circumference; II – with increased BMI and waist circumference / hip circumference. The control group consisted of 25 people. According to the analysis of the obtained results of this study, a direct relationship was revealed between the BMI value, the indicator of abdominal obesity (waist circumference / hip circumference) and changes in the ultrasonic echostructure of the liver, pancreas, linear dimensions of the liver and the stiffness of the liver tissue. The early signs of MS included: 1. Increased echogenicity and decreased sound conductivity of the liver structure. 2. Hepatomegaly (an increase in the linear dimensions of the liver: craniovertical size (right lobe) more than 150 mm, craniocaudal size (left lobe) more than 100 mm, caudate lobe more than 54 mm) was detected in 51 people of subgroup II (40.8 %) (p < 0.05). 3. Changes in the ultrasonic structure of the contents and wall of the gallbladder, polyposis. 4. Increasing the echogenicity of the pancreatic tissue.

The article presents the results of a study conducted to identify early significant markers of metabolic syndrome (MS) based on non-invasive visualization of the internal organs of the abdominal cavity. The study included 125 people, 100 people of the main group were divided into two subgroups. Subgroup I – patients with normative values of body mass index (BMI), but with increased indices of the waist circumference / hip circumference; II – with increased BMI and waist circumference / hip circumference. The control group consisted of 25 people. According to the analysis of the obtained results of this study, a direct relationship was revealed between the BMI value, the indicator of abdominal obesity (waist circumference / hip circumference) and changes in the ultrasonic echostructure of the liver, pancreas, linear dimensions of the liver and the stiffness of the liver tissue. The early signs of MS included: 1. Increased echogenicity and decreased sound conductivity of the liver structure. 2. Hepatomegaly (an increase in the linear dimensions of the liver: craniovertical size (right lobe) more than 150 mm, craniocaudal size (left lobe) more than 100 mm, caudate lobe more than 54 mm) was detected in 51 people of subgroup II (40.8 %) (p < 0.05). 3. Changes in the ultrasonic structure of the contents and wall of the gallbladder, polyposis. 4. Increasing the echogenicity of the pancreatic tissue.

ultrasound diagnosticsmetabolic syndromesteatohepatosisultrasound diagnosticsmetabolic syndromesteatohepatosisСписок литературыDenisov N.L., Grinevich V.B., Chernecova E.V., Kornouhova L.A., Vostrikova E.B., Chuprina S.V., Potapova I.V. 2017. Sovremennye koncepcii patogeneza ateroskleroticheskogo porazhenija sosudistoj stenki u pacientov s abdominal'nym ozhireniem i razlichnymi formami nealkogol'noj zhirovoj bolezni pecheni [Modern concepts of the pathogenesis of atherosclerotic lesions of the vascular wall in patients with abdominal obesity and various forms of non-alcoholic fatty liver disease]. Vestnik Nacional'nogo mediko-hirurgicheskogo Centra im. N.I. Pirogova. 1: 57–62.Deomidova V.N., Petrova O.V.2013. Sravnitel'nyj analiz rezul'tatov jelastografii sdvigovoj volnoj i tranzientnojjelastografii v diagnostike diffuznyh zabolevanij pecheni [Comparative analysis of the results of shear wave elastography and transient elastography in the diagnosis of diffuse liver diseases]. Ul'trazvukovaja i funkcional'naja diagnostika. 5: 17–22.Kilina O.Yu., Khanarin N.V., Ivanova S.N., Rossova N.A. 2015. Diagnosticheskiye vozmozhnosti ul'trazvukovogo issledovaniya s otsenkoy gepatorenal'nogo indeksa v diagnostike nealkogol'noy zhirovoy bolezni pecheni u bol'nykh metabolicheskim sindromom [Diagnostic capabilities of ultrasound examination with an assessment of hepatorenal index in the diagnosis of non-alcoholic fatty liver disease in patients with metabolic syndrome]. Vestnik KHGU im. N.F. Katanova. 12: 56–59.Kosobjan E.P., Smirnova O.M. 2010. Sovremennye koncepcii patogeneza nealkogol'noj zhirovoj bolezni pecheni [Modern concepts of the pathogenesis of non-alcoholic fatty liver disease]. Saharnyj diabet. 1: 55–63.Lelyuk V.G., Lelyuk S.E. 2003. Ul'trazvukovaya angiologiya [Ultrasound Angiology]. 2-ye izdaniye, dopiperer. Moskva. 336 s.Mit'kov V.V. 2011. Prakticheskoye rukovodstvo po ul'trazvukovoy diagnostike. Obshchaya ul'trazvukovaya diagnostika [A practical guide to ultrasound diagnostics. General ultrasound diagnostics]. Moskva. Vidar. 720 s.Nedogoda S.V., Sanina T.N., Chaljabi T.A., Barykina I.N., Coma V.V., Chumachek E.V., Salasjuk A.S., Hripaeva V.Ju., Smirnova V.O. 2014. Diagnostika i osobennosti lechenija nealkogol'noj zhirovoj bolezni pecheni u pacientov s metabolicheskim sindromom: vozmozhnosti kardiologicheskih i saharosnizhajushhih preparatov [Diagnostics and treatment features of non-alcoholic fatty liver disease in patients with metabolic syndrome: the possibilities of cardiological and hypoglycemic drugs]. MS. 11: 66–69.Tikhonov A.I., Khvorostinka V.N., Yefremova O.A., Yarnykh T.G., Pushkar S.N., Kotenko A.M. 1994. Sredstvo, obladayushcheye antioksioksidantnym i gepatozashchitnym svoystvami [An agent with antioxidant and hepatoprotective properties]. Patent naizobreteniye RU 2020946 C1, 15.10.1994. Zayavka № 4864094/14 ot 05.09.1990.Khaybullina Z.R., Kosnikova I.V. 2014. Proyavleniya metabolicheskogo sindroma u bol'nykh mul'tifokal'nym aterosklerozom [Manifestations of metabolic syndrome in patients with multifocal atherosclerosis].Vestnik NGPU. 5 (21): 127–133.Chesnokova L.V., Petrov I.M., Troshina I.A., Medvedeva I.V. 2014. Insulinorezistentnost', aterogennyye narusheniya i fibroz pecheni u bol'nykh s metabolicheskim sindromom [Insulin resistance, atherogenic disorders and liver fibrosis in patients with metabolic syndrome]. Ozhireniye i metabolizm. 2: 17–23.Abenavoli L., Milic N., Di Renzo L., Preveden T., Medić-Stojanoska M., De Lorenzo A. 2016. Metabolic aspects of adult patients with nonalcoholic fatty liver disease. World. J. Gastroenterol. Aug 21; 22 (31): 7006–16.Bhandarkar N.S., Brown L., Panchal S.K. 2019. Chlorogenic acid attenuates highcarbohydrate, high-fat diet-induced cardiovascular, liver, and metabolic changes in rats. Nutrition research. 62: 78–88.Browning J.D., Kumar K.S., Saboorian M.H., Thiele D.L. 2004. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am. J. Gastroenterol, 99: 292–298.Ikura Y. 2014. Transitions of histopathologic criteria for diagnosis of nonalcoholic fatty liver disease during the last three decades 12 (6): 894–900. World. J. Hepatol. 923–928.Chaix A., Lin T., Le H.D., Chang M.W., Panda S. 2019. Time-restricted feeding prevents obesity and metabolicome in mice lacking a circadian clock. Cell metabolism. 29 (2): 303–319.Käräjämäki A.J., Bloigu R., Kauma H., Kesäniemi Y.A., Koivurova O., Perkiömäki J., Huikuri H., Ukkola O. 2017. Non-alcoholic fatty liver disease with and without metabolic syndrome: different long-term outcomes. Metabolism. 66: 55–63.Kim D., Touros A., Kim W.R. 2018. Nonalcoholic fatty liver disease and metabolic syndrome. Clinics in liver disease. 22 (1): 133–140.Lin Y.H., Liao Y.Y., Yeh C.K., K.C. Yang., Tsui P.H. 2018. Ultrasound entropy imaging of nonalcoholic fatty liver disease: Association with metabolic syndrome/entropy. 20 (12): 893.Lucero D., Miksztowicz V., Gualano G., Longo C., Landeira G., Álvarez E., Zago V., Brites F., Berg G., Fassio E., Schreier L. 2017. Nonalcoholic fatty liver disease associated with metabolic syndrome: influence of liver fibrosis stages on characteristics of very low-density lipoproteins. Clinica chimicaacta. 473: 1–8.Sebastiani G., Alshaalan R., Wong P., Rubino M., Salman A., Metrakos P., Deschenes M., Ghali P. 2015. Cardiovascular risk across the histological spectrum and the clinical manifestations of nonalcoholic fatty liver disease: An update. 2015 Jun 14; 21 (22): 6820–34. doi: 10.3748/wjg.v21.i22.6820. World J Gastroenterol. 102–107.